ѻý

MedpageToday
ASCO > Lung Cancer

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA NSCLC (NADIM Phase II trial)

<ѻý class="mpt-content-deck">– An ASCO Reading Room selection
Mariano Provencio, MD, PhD; Roberto Serna-Blasco, MSc; Ernest Nadal, MD; Amelia Insa, MD; M. Rosario García-Campelo, MD; Joaquín Casal Rubio, MD; Manuel Dómine, MD6; Margarita Majem, MD; Delvys Rodríguez-Abreu, MD; Alex Martínez-Martí, MD; Javier De Castro Carpeño, MD; Manuel Cobo, MD; Guillermo López Vivanco, MD; Edel Del Barco, MD; Reyes Bernabé Caro, MD; Nuria Viñolas, MD; Isidoro Barneto Aranda, MD; Santiago Viteri, MD; Eva Pereira, MSc; Ana Royuela, PhD; Virginia Calvo, MD; Javier Martín-López, MD; Francisco García-García, PhD; Marta Casarrubios, MSc; Fernando Franco, MD; Estela Sánchez-Herrero, MSc; Bartomeu Massuti, MD; Alberto Cruz-Bermúdez, PhD; and Atocha Romero, PhD
Journal of Clinical Oncology

This Reading Room is a collaboration between ѻý® and:

Medpage Today
Below is the abstract of the article.
Read the full article PDF by clicking here
or on the link below.

Purpose

Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier: ). The 3-year overall survival (OS) and circulating tumor DNA (ctDNA) analysis have not been reported.

Methods

This was an open-label, multicenter, single-arm, phase II trial in which patients with stage IIIA NSCLC, who were deemed to be surgically resectable, were treated with neoadjuvant paclitaxel (200 mg/m2 once a day) and carboplatin (area under curve 6) plus nivolumab (360 mg) once on day 1 of each 21-day cycle, for three cycles, followed by adjuvant nivolumab monotherapy for 1 year (240 mg once every 2 weeks for 4 months, followed by 480 mg once every 4 weeks for 8 months). The 3-year OS and ctDNA analysis were secondary objectives of the trial.

Results

OS at 36 months was 81.9% (95% CI 66.8 to 90.6) in the intention-to-treat population, rising to 91.0% (95% CI 74.2 to 97.0) in the per-protocol population. Neither tumor mutation burden nor programmed cell death ligand-1 staining was predictive of survival. Conversely, low pretreatment levels of ctDNA were significantly associated with improved progression-free survival and OS (hazard ratio [HR] 0.20, 95% CI 0.06 to 0.63, and HR 0.07, 95% CI 0.01 to 0.39, respectively). Clinical responses according to RECIST v1.1 criteria did not predict survival outcomes. However, undetectable ctDNA levels after neoadjuvant treatment were significantly associated with progression-free survival and OS (HR 0.26, 95% CI 0.07 to 0.93, and HR 0.04, 95% CI 0.00 to 0.55, respectively). The C-index to predict OS for ctDNA levels after neoadjuvant treatment (0.82) was superior to that of RECIST criteria (0.72).

Conclusion

The efficacy of neoadjuvant chemotherapy plus nivolumab in resectable NSCLC is supported by 3-year OS. ctDNA levels were significantly associated with OS and outperformed radiologic assessments in the prediction of survival.

Read an interview about the study here and expert commentary about the clinical implications here.

Read the full article

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA NSCLC (NADIM Phase II trial)

Primary Source

Journal of Clinical Oncology

Source Reference:

ASCO Publications Corner

ASCO Publications Corner